Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting of glycosylation pathways to empower CAR-T therapy of solid tumors.

Project description

Enhancing CAR T cell therapy of solid tumours

Chimeric antigen receptor (CAR) T cell therapy offers long-term protection against tumour recurrence, particularly in advanced-stage leukaemia. However, this is not the case with solid tumours due to the immunosuppressive environments they create. Research shows that targeting the CAR T cell glycocalyx (specifically, a single glycogene) in mice significantly improved tumour clearance. This demonstrates a promising direction for enhancing CAR T therapy against solid tumours. The ERC-funded GlycoCAR project aims to target the glycocalyx of CAR T cells. The project has developed a programme to build upon existing findings and to investigate a candidate set of glycosylation engineering concepts in CAR T cells. The project’s overall goal is to boost CAR T therapy in the treatment of solid tumours.

Objective

Chimeric Antigen Receptor (CAR) T cell therapy uniquely can provide life-long protection against tumor re-emergence upon clearance of even advanced-stage leukemia. However, for the more frequent solid tumor types (carcinomas, lymphomas), clearance of advanced-stage tumors, and especially the subsequent long-term protection, is only rarely achieved. The main reason for this is the multi-pathway immunosuppressive environment that these tumors evolve to overcome the selective pressure imposed by the patient’s immune system. This both hampers the initial attack by CAR-Ts, and often leads to low numbers of long-term persisting CAR-T cells, which tend to be in a state of functional exhaustion. Most attempts at overcoming this, target particular CAR-T cell proteins involved in individual pathways of immunosuppression. However, it is clear from early-stage clinical trials with such engineered CAR-T cells that multiple pathways will need to be tackled at the same time. Inspired by this challenge, I have chosen a radically different path: we are targeting the CAR-T cell glycocalyx, i.e. the assembly of glycosylated structures that forms the outer layer of the cell. The unique property of glycosylation pathways is that they often modulate a large range of cell surface receptor biology at the same time.
Excitingly, this new research line has now generated the first highly promising results with the discovery of a single CAR-T glycogene inactivation that results in robust clearance of a benchmark highly immunosuppressive carcinoma rechallenge, in mice that were CAR-T cured from their primary tumor months earlier. Encouraged by these exciting results that demonstrate strong long-term functional persistence of these glyco-engineered CAR-T cells, we have defined a programme to build on this finding and to explore a candidate set of further glycosylation engineering concepts in CAR-T cells, to further improve CAR-T therapy of solid tumors.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-ADG

See all projects funded under this call

Host institution

VIB VZW
Net EU contribution
€ 2 498 435,00
Address
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Research Organisations
Links
Total cost
€ 2 498 435,00

Beneficiaries (1)